PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.68%
Cash & equivalents yoy growth below half of GNPX's 72.29%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
13.68%
Below half of GNPX's 72.29%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
13.59%
Below half of GNPX's 64.01%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-11.93%
≥ 1.5x GNPX's -5.43%. David Dodd sees more aggressive capex. Confirm it's not overspending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-88.66%
Higher Other Non-Current Assets Growth compared to GNPX's zero value, indicating worse performance.
-8.29%
Below half of GNPX's 1.06%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
13.10%
Below half of GNPX's 62.71%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-14.12%
Less than half of GNPX's 75.66%. David Dodd sees a more disciplined AP approach or lower volume.
2.34%
Higher Short-Term Debt Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
14.12%
Higher Deferred Revenue (Current) Growth compared to GNPX's zero value, indicating better performance.
-2.34%
Less than half of GNPX's 6.56%. David Dodd sees fewer expansions in other current obligations.
-12.65%
Less than half of GNPX's 36.14%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-36.66%
Higher Total Non-Current Liabilities Growth compared to GNPX's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-14.12%
Less than half of GNPX's 36.14%. David Dodd sees far fewer liability expansions relative to competitor.
5.56%
50-75% of GNPX's 9.73%. Bruce Berkowitz notes minimal new equity relative to competitor.
-2.30%
Below half GNPX's -11.11%. Michael Burry suspects major net losses or high dividends vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
15.36%
Below half GNPX's 63.09%. Michael Burry sees potential underperformance in building shareholder capital.
13.10%
Below half GNPX's 62.71%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-14.09%
Higher Total Debt Growth compared to GNPX's zero value, indicating worse performance.
-14.00%
Less than half of GNPX's -72.29%. David Dodd sees better deleveraging or stronger cash buildup than competitor.